ANDA 203114, held by Osmotica Pharm US. Donepezil Hydrochloride.
As of Nov 16, 2026, ANDA 203114 (Donepezil Hydrochloride), held by Osmotica Pharm US, was first approved by FDA on Jan 26, 2016, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 26, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Donepezil Hydrochloride23MG · tablet;oral | Donepezil Hydrochloride | Discontinued |
| Apr 18, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 26, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters